Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
FLOW CYTOMETRY SHARED RESOURCE: PROJECT SUMMARY
The Flow Cytometry Shared Resource (FCSR) gives access to flow cytometry analysis and cell sorting
instruments and services to Herbert Irving Comprehensive Cancer Center (HICCC) members. Under the
leadership of Remi Creusot, PhD, the FCSR provides: (1) multi-color panel flow data acquisition and analysis
using flow cytometry analyzers, including high throughput screening (HTS), (2) flow cytometry cell sorting (four-
way or six-way or plate) using high speed cell sorters by dedicated operators of FCSR, including single cell index
sorting, and (3) comprehensive consultation, panel design, hands-on training, troubleshooting, and data analysis
services by PhD-level FCSR scientists. This broad and inclusive package of services enables HICCC
investigators to analyze tumor cell populations and their microenvironment, including the tumor-infiltrating
lymphoid and myeloid cells at the single cell level. During the current project period (2014-2019), the FCSR has
been integrated with the flow cytometry core of the Columbia Center for Translational Immunology (CCTI). The
merging of these facilities has secured access to a broader range of state-of-the-art instrumentation and brought
advanced expertise in immunology to the research of HICCC flow cytometry users. HICCC members now have
access to nine instruments, including five analyzers and four sorters. In addition, two of the existing
instruments/analyzers have been upgraded to 18-20 detectors. Moreover, a new Influx sorter has been acquired
to expand the capacity of sorting services. Upgrades in consultation services have further empowered the
research of HICCC members who now benefit from face-to-face consultation on panel design, protocol
optimization, and hands-on training on data acquisition, analysis, and experimental troubleshooting essential to
maximize the impact of new advanced instruments for high dimensional multi-color panels. Based on its
advanced instrumentation, highly qualified staff, broad portfolio of specialized services, easy accessibility, and
cost-effective services, the FCSR is the flow cytometry service provider of choice for HICCC members. The
FCSR will continue to incorporate the latest technologies and to provide high quality cell sorting, analytical and
consultation services to HICCC members to empower their understanding of cancer biology and to enable new
breakthroughs in cancer therapy. Over the current project period, the capabilities of the FCSR have been utilized
by 81 HICCC members, provided key data and insights to support the success of more than 46 HICCC member
peer-reviewed publications, including 23 contributions in journals with impact factor >10, of which 12 were in
journals with an impact factor >20 (Nature, Cell Stem Cell, Cancer Cell, Cancer Discovery), and currently support
research for 21 NIH-funded research grants (11 from NCI).
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Cancer BiologyCancer Center Support GrantCell SeparationCell surfaceCellsColorComplexComputer softwareComputers and Advanced InstrumentationConceptionsConsultationsDataData AnalysesDedicationsDevelopmentDoctor of PhilosophyEducationEquipmentEventFlow CytometryFlow Cytometry Shared ResourceFundingGoalsHematopoieticHerbert Irving Comprehensive Cancer CenterHourHuman ResourcesImmuneImmunologyInfiltrationInfrastructureIntracellular Signaling ProteinsJournalsLasersLeadershipLymphoid CellMaintenanceMalignant NeoplasmsManuscriptsMetabolic MarkerMyeloid CellsNatureNeeds AssessmentPeer ReviewPopulationPreparationProtocols documentationPublicationsQualifyingReproducibilityResearchResearch PersonnelResearch Project GrantsResearch SupportSamplingScientistSecureServicesSolidSortingSpeedStainsTechniquesTechnologyTimeTrainingTraining and EducationTreesUnited States National Institutes of HealthWalkinganti-cancer researchcancer cellcancer immunotherapycancer therapycomplex datacost effectivecost effectivenessdata acquisitiondensitydesigndetectorempowermentexperiencehigh dimensionalityhigh standardhigh throughput screeningindexinginsightinstrumentinstrumentationleukemia/lymphomamembermultidimensional dataneoplastic cellnew technologynovelprogramsprospectiveservice providersstem cellssuccesstechnology developmenttechnology validationtooltranscription factortranslational immunologytumortumor immunology
No Sub Projects information available for 5P30CA013696-49 5601
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA013696-49 5601
Patents
No Patents information available for 5P30CA013696-49 5601
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA013696-49 5601
Clinical Studies
No Clinical Studies information available for 5P30CA013696-49 5601
News and More
Related News Releases
No news release information available for 5P30CA013696-49 5601
History
No Historical information available for 5P30CA013696-49 5601
Similar Projects
No Similar Projects information available for 5P30CA013696-49 5601